IPP Bureau
Oval Fertility launches in Hyderabad, introduces Astec Chronos AI-powered IVF tech to India
By IPP Bureau - June 01, 2026
Aims to bridge transparency gaps in fertility care, with focus on successful patient outcomes, placing healthy live birth outcomes at the centre of treatment journeys
Pantherna acquisition to boost T-CURX’s clinical translation of non-viral In Vivo CAR-T strategies
By IPP Bureau - June 01, 2026
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
Ardena appoints Ariane de Ganck as Chief Scientific Officer
By IPP Bureau - June 01, 2026
Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022
Indoco's formulation plant at Baddi receives EU GMP certification
By IPP Bureau - June 01, 2026
This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive
Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%
By IPP Bureau - May 31, 2026
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia
By IPP Bureau - May 31, 2026
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial
By IPP Bureau - May 30, 2026
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting
By IPP Bureau - May 30, 2026
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
Glenmark posts strong FY26 results with 27.5% revenue jump
By IPP Bureau - May 30, 2026
Lupin wins FDA nod for generic colonoscopy prep drug with first-to-file exclusivity
By IPP Bureau - May 30, 2026
Crucially, Lupin is the exclusive first-to-file applicant for this product and is eligible for 180-day generic drug exclusivity in the U.S. market
AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial
By IPP Bureau - May 30, 2026
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough
By IPP Bureau - May 30, 2026
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
FDA delays AstraZeneca decision on camizestrant as regulators seek more data
By IPP Bureau - May 30, 2026
The filing is backed by results from the pivotal SERENA-6 Phase III trial
Lupin secures FDA nod for generic Sutab tablets with 180-day exclusivity
By IPP Bureau - May 30, 2026
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
Fermenta Biotech reports 26% revenue growth in FY26
By IPP Bureau - May 30, 2026
